USTR’s investigation under Section 301 of the Trade Act of 1974, filed June 18 against Germany’s drug pricing, treats a foreign country’s health insurance deficit as America’s trade problem. That framing matters.
Ambassador Jamieson Greer cited Germany’s draft healthcare savings law, designed to save more than €16 billion ($18.3 billion) in healthcare spending, as evidence of a trading partner moving backward on R&D burden-sharing. Germany’s state insurance deficit is forecast to grow from €15.3 billion in 2027 to €40.4 billion by 2030, and Berlin pitched the cuts as a fiscal necessity. Both Eli Lilly CEO David Ricks and Boehringer Ingelheim read the signal differently: both companies pulled planned German manufacturing investments before Germany dropped one of the law’s most contentious provisions.
The probe names two potential remedies: confidential supplemental discounts and mandatory variable rate rebates. They’re bilateral pricing tools. The structural target is Germany’s AMNOG system and the value it assigns to patented medicines.
Greer’s template is the UK-US pharma deal signed April 2: London increased NHS payments for new medicines by 25% and capped branded drug rebates at 15% in exchange for zero tariffs on pharma exports. Germany is being handed the same offer. France and Canada run structurally similar HTA-driven pricing frameworks. If Berlin settles on supplemental discounts or rebate caps, those systems face the same pressure. What Germany concedes here doesn’t stay in Germany.
A public hearing is scheduled for September 22. Worth reviewing your market access exposure across AMNOG and comparable HTA markets before comments close August 10.
Rebecca Lauren